Home Cart Sign in  
Chemical Structure| 168646-54-6 Chemical Structure| 168646-54-6
Chemical Structure| 168646-54-6
Product Citations

Product Citations

Pickens, Rachael N ;

Abstract: The goal of this research was to design and study new systems of light activated molecules to deliver therapeutic agents. The impact of structural variation on spectroscopic properties as well as changes in photoinduced release of therapeutic molecules is reported herein. Chapter 2 reports complexes with the general structure [(bpy)2Ru(BL)Mn(CO)3Br](PF6)2 where the BL = 2,3-bis(2-pyridyl)pyrazine (dpp) and 2,2ʹ-bipyrimidine (bpm) and bpy = 2,2-bipyridine. Each of the bidentate bridging ligands exhibit different degrees of π-accepting ability when bridging two metal cations. The impact of the choice of bridging ligand on the photoactivated release of both CO and singlet oxygen (1O2) is reported. This report is the first example of a Ru(II),Mn(I) bimetallic complex with photoactivity in the phototherapy window (600 – 900 nm). The complexes were found to be stable in the dark and only released CO and singlet oxygen upon exposure to visible light. Chapter 3 extends the types of photoactivity of the complexes to include photoactivated DNA intercalation, along with CO release and 1O2 production. The framework used in this study was [(bpy)2Ru(tpphz)Mn(CO)3Br](PF6)2 where bpy = 2,2-bipyridine and tpphz = tetrapyrido[3,2-a:2′,3′-c:3′′,2′′-h:2′′′,3′′′- j]phenazine. The previously studied [Ru(bpy)2(tpphz)](PF6)2 complex has the ability to intercalate between the base pairs of DNA, which can inhibit cell proliferation, as well as a high production efficiency of singlet oxygen when exposed to light. This study used the 4 framework studied in chapter 2 and incorporated the tpphz as a bridging ligand component. The purpose of this study was to test if the addition of the Mn moiety would continue to allow interaction of the tpphz to DNA or inhibit it. The study found that the complex is stable in the dark and inhibits DNA intercalation in the dark. When exposed to visible light, the Mn component dissociates from the complex, freeing the tpphz to then intercalate into DNA. To the best of our knowledge, this is only the second reported photoactivated intercalative binding of an inorganic complex to DNA. Chapter 4 investigates the structure of the Mn(I) component on the energy of light required for photoactivation. A series of Mn(I) monometallic and bimetallic complexes were investigated for their ability to release CO when exposed to visible light. The framework studied was fac-[Mn(BL)(CO)3Br] and fac-[Br(CO)3Mn(BL)Mn(CO)3Br] for the monoand bimetallic complexes respectively where BL = 2,3-Bis(2-pyridyl)-pyrazine (dpp), 2,3-Bis(2-pyridyl)quinoxaline (dpq), and 2,3-bis(2-pyridyl)benzoquinoxaline (dpb). The bridging ligands, which have increasing π-accepting ability from dpp  dpq  dpb, allowed for lower energy absorbance and lower energy light required to release the CO. All of these complexes were able to release all CO molecules using visible light, which extended into the phototherapy window for some of the structures studied.

Purchased from AmBeed:

Alternative Products

Product Details of [ 168646-54-6 ]

CAS No. :168646-54-6
Formula : C12H10N4
M.W : 210.24
SMILES Code : NC1=C(N)C2=C(N=CC=C2)C2=NC=CC=C12
MDL No. :MFCD12913573
InChI Key :MNXMBMNXSPNINS-UHFFFAOYSA-N
Pubchem ID :10910805

Safety of [ 168646-54-6 ]

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Calculated chemistry of [ 168646-54-6 ] Show Less

Physicochemical Properties

Num. heavy atoms 16
Num. arom. heavy atoms 14
Fraction Csp3 0.0
Num. rotatable bonds 0
Num. H-bond acceptors 2.0
Num. H-bond donors 2.0
Molar Refractivity 65.85
TPSA ?

Topological Polar Surface Area: Calculated from
Ertl P. et al. 2000 J. Med. Chem.

77.82 Ų

Lipophilicity

Log Po/w (iLOGP)?

iLOGP: in-house physics-based method implemented from
Daina A et al. 2014 J. Chem. Inf. Model.

0.97
Log Po/w (XLOGP3)?

XLOGP3: Atomistic and knowledge-based method calculated by
XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry

1.1
Log Po/w (WLOGP)?

WLOGP: Atomistic method implemented from
Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.

1.96
Log Po/w (MLOGP)?

MLOGP: Topological method implemented from
Moriguchi I. et al. 1992 Chem. Pharm. Bull.
Moriguchi I. et al. 1994 Chem. Pharm. Bull.
Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.

0.67
Log Po/w (SILICOS-IT)?

SILICOS-IT: Hybrid fragmental/topological method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

1.47
Consensus Log Po/w?

Consensus Log Po/w: Average of all five predictions

1.24

Water Solubility

Log S (ESOL):?

ESOL: Topological method implemented from
Delaney JS. 2004 J. Chem. Inf. Model.

-2.48
Solubility 0.69 mg/ml ; 0.00328 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Soluble
Log S (Ali)?

Ali: Topological method implemented from
Ali J. et al. 2012 J. Chem. Inf. Model.

-2.33
Solubility 0.99 mg/ml ; 0.00471 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Soluble
Log S (SILICOS-IT)?

SILICOS-IT: Fragmental method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

-4.29
Solubility 0.0107 mg/ml ; 0.0000511 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Moderately soluble

Pharmacokinetics

GI absorption?

Gatrointestinal absorption: according to the white of the BOILED-Egg

High
BBB permeant?

BBB permeation: according to the yolk of the BOILED-Egg

No
P-gp substrate?

P-glycoprotein substrate: SVM model built on 1033 molecules (training set)
and tested on 415 molecules (test set)
10-fold CV: ACC=0.72 / AUC=0.77
External: ACC=0.88 / AUC=0.94

Yes
CYP1A2 inhibitor?

Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.83 / AUC=0.90
External: ACC=0.84 / AUC=0.91

Yes
CYP2C19 inhibitor?

Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.80 / AUC=0.86
External: ACC=0.80 / AUC=0.87

No
CYP2C9 inhibitor?

Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set)
and tested on 2075 molecules (test set)
10-fold CV: ACC=0.78 / AUC=0.85
External: ACC=0.71 / AUC=0.81

No
CYP2D6 inhibitor?

Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set)
and tested on 1068 molecules (test set)
10-fold CV: ACC=0.79 / AUC=0.85
External: ACC=0.81 / AUC=0.87

Yes
CYP3A4 inhibitor?

Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set)
and tested on 2579 molecules (test set)
10-fold CV: ACC=0.77 / AUC=0.85
External: ACC=0.78 / AUC=0.86

Yes
Log Kp (skin permeation)?

Skin permeation: QSPR model implemented from
Potts RO and Guy RH. 1992 Pharm. Res.

-6.8 cm/s

Druglikeness

Lipinski?

Lipinski (Pfizer) filter: implemented from
Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev.
MW ≤ 500
MLOGP ≤ 4.15
N or O ≤ 10
NH or OH ≤ 5

0.0
Ghose?

Ghose filter: implemented from
Ghose AK. et al. 1999 J. Comb. Chem.
160 ≤ MW ≤ 480
-0.4 ≤ WLOGP ≤ 5.6
40 ≤ MR ≤ 130
20 ≤ atoms ≤ 70

None
Veber?

Veber (GSK) filter: implemented from
Veber DF. et al. 2002 J. Med. Chem.
Rotatable bonds ≤ 10
TPSA ≤ 140

0.0
Egan?

Egan (Pharmacia) filter: implemented from
Egan WJ. et al. 2000 J. Med. Chem.
WLOGP ≤ 5.88
TPSA ≤ 131.6

0.0
Muegge?

Muegge (Bayer) filter: implemented from
Muegge I. et al. 2001 J. Med. Chem.
200 ≤ MW ≤ 600
-2 ≤ XLOGP ≤ 5
TPSA ≤ 150
Num. rings ≤ 7
Num. carbon > 4
Num. heteroatoms > 1
Num. rotatable bonds ≤ 15
H-bond acc. ≤ 10
H-bond don. ≤ 5

0.0
Bioavailability Score?

Abbott Bioavailability Score: Probability of F > 10% in rat
implemented from
Martin YC. 2005 J. Med. Chem.

0.55

Medicinal Chemistry

PAINS?

Pan Assay Interference Structures: implemented from
Baell JB. & Holloway GA. 2010 J. Med. Chem.

0.0 alert
Brenk?

Structural Alert: implemented from
Brenk R. et al. 2008 ChemMedChem

3.0 alert: heavy_metal
Leadlikeness?

Leadlikeness: implemented from
Teague SJ. 1999 Angew. Chem. Int. Ed.
250 ≤ MW ≤ 350
XLOGP ≤ 3.5
Num. rotatable bonds ≤ 7

No; 1 violation:MW<1.0
Synthetic accessibility?

Synthetic accessibility score: from 1 (very easy) to 10 (very difficult)
based on 1024 fragmental contributions (FP2) modulated by size and complexity penaties,
trained on 12'782'590 molecules and tested on 40 external molecules (r2 = 0.94)

1.66

Application In Synthesis [ 168646-54-6 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Downstream synthetic route of [ 168646-54-6 ]

[ 168646-54-6 ] Synthesis Path-Downstream   1~2

  • 1
  • [ 2631-77-8 ]
  • [ 168646-54-6 ]
  • 2-(2-hydroxy-3,5-diiodophenyl)-1H-imidazo[4,5-f][1,10]phenanthroline [ No CAS ]
YieldReaction ConditionsOperation in experiment
80.9% In ethanol; for 12h;Inert atmosphere; Schlenk technique; Reflux; The ligand L3 was prepared by the following procedure. The mixture of <strong>[2631-77-8]3,5-diiodosalicylaldehyde</strong> (1.00 mmol, 1 equiv) and dap (1.00 mmol, 1 equiv) was refluxed in ethanol (20 mL) for12 h, then the mixture was concentrated under vacuo and cooled to room temperature. After filtration, the orange-yellow precipitate was washed three times by cold ethanol and dried in vacuo.Yield: 80.9%. Anal. Calcd for C19H10I2N4O (563.89): C 40.43, H1.79, N 9.93. Found: C 40.57, H 1.86, N 9.85. ESI-MS (m/z):564.9019 [M+H+] (calcd 564.9017); 562.885 [M-H+] (calcd562.886). 1H NMR (400 MHz, CD2Cl2, d, ppm): 14.14 (s, br, 2H, NH + OH), 9.08 (d, J = 2.8 Hz, 2H), 8.93 (s, br, 2H), 8.53 (s, br, 1H),8.15 (d, J = 2.0 Hz, 1H), 7.89 (s, br, 2H). IR spectrum (KBr, cm1):3444w, 3159m, 3121m, 3062s, 2965s, 2861s, 1609m, 1592m,1563m, 1539m, 1506m, 1582m, 1436s, 1402s, 1375m, 1356m,1296w, 1271m, 1256m, 1199w, 1178w, 1146w, 1123w, 1088w,1070m, 1049m, 1030m, 1002w, 976w, 940w, 880w, 864w, 800s,738s, 699w, 667m, 655m, 636m.
  • 2
  • [ 37091-73-9 ]
  • [ 168646-54-6 ]
  • C22H26N8 [ No CAS ]
 

Historical Records

Technical Information

Categories